Dr. Deliargyris Brings More Than 25 Years
of Expertise in Cardiovascular Medicine, Academia and the Biotech
Industry
PLx Pharma Inc. (Nasdaq:PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Aspertec™ 325 mg and
Aspertec™ 81 mg (referred to together as “Aspertec”™), today
announced the addition of Efthymios N. Deliargyris, MD, FACC, FESC,
FSCAI, as Chief Medical Advisor.
Dr. Deliargyris, an internationally-recognized expert in the
field of thrombosis, brings to PLx Pharma deep knowledge in
cardiovascular medicine and extensive experience in the development
and commercialization of antithrombotic agents. In his new role, he
will oversee critical scientific and medical affairs activities
that are expected to advance the market readiness of U.S. Food and
Drug Administration (FDA) approved Aspertec 325 mg, a liquid-filled
aspirin capsule for over-the-counter distribution.
“We are pleased to welcome Dr. Deliargyris to the PLx Pharma
team at a time when we are building our commercial operations in
anticipation of the future launch of Aspertec,” said Natasha
Giordano, President and Chief Executive Officer of PLx Pharma. “Dr.
Deliargyris’ decades of experience and proven track record will be
instrumental in communicating the clinical value of Aspertec, and
engaging the academic community to maximize advocacy and support
for this unique product.”
“I’m excited to contribute to the commercial launch of Aspertec,
a novel aspirin formulation with the potential to benefit millions
of patients with, or at risk for, cardiovascular disease,” stated
Dr. Deliargyris. “PLxGuard’s innovative new technology is designed
to provide fast, predictable antiplatelet efficacy and targeted
aspirin delivery. These differentiating features of Aspertec have
the potential to address the unmet medical need for an aspirin
product with less clinical resistance and fewer gastrointestinal
side effects. The clinical implications and competitive advantages
are significant. I am looking forward to working with PLx to bring
a best-in-class aspirin product to market and raise the standard of
care for cardiovascular patients.”
Previously, Dr. Deliargyris held positions of increasing
responsibility at The Medicines Company where as Vice President and
Global Medical Lead for Acute Cardiovascular Care he was in charge
of a globally-marketed cardiovascular portfolio, global medical
affairs, post-marketing research and development as well as New
Drug Application (NDA) and Marketing Authorisation Application
(MAA) submissions.
Earlier in his career Dr. Deliargyris was a practicing
interventional cardiologist both in the U.S. and Europe and served
as Chief, Section of Cardiology & Interventional Cardiology at
Athens Medical Center, Athens, Greece; as well as Assistant
Professor of Cardiology at Wake Forest University School of
Medicine, Winston-Salem, NC.
In addition to his extensive clinical background, Dr.
Deliargyris is also internationally recognized for his original
research in cardiovascular disease and thrombosis. He has authored
more than 80 papers in the top peer reviewed journals including the
New England Journal of Medicine, Journal of the American College of
Cardiology, Circulation and European Heart Journal. His original
research has been recognized with multiple awards, including the
prestigious Society for Cardiovascular Angiography and
Interventions (SCAI) Fellowship Award in 1999 for best original
research in interventional cardiology in the U.S.
About AspertecAspertec 325 mg is
an FDA-approved aspirin product being developed to provide
high-risk cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric-coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on completing manufacturing
scale-up and label finalization for Aspertec 325 mg aspirin dosage
form and preparing an sNDA for Aspertec 81 mg maintenance dose
form.
About PLx Pharma Inc.PLx Pharma
Inc. is a late-stage specialty pharmaceutical company focused
on developing its clinically validated and patent-protected
PLxGuard™ delivery system to provide safe and effective aspirin
products. The PLxGuard delivery system works by targeting delivery
of active pharmaceutical ingredients (API) to various portions of
the gastrointestinal (GI) tract. PLx believes this has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce acute GI side
effects—including erosions, ulcers and bleeding—associated with
aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Forward-Looking StatementsAny statements made
in this press release relating to future financial or business
performance, conditions, plans, prospects, trends, or strategies
and other financial and business matters, including without
limitation, the prospects for commercializing or selling any
products or drug candidates, are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. In addition, when or if used in this press release, the words
“may,” “could,” “should,” “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “plan,” “predict” and similar expressions and
their variants, as they relate to PLx may identify forward-looking
statements. PLx cautions that these forward-looking statements are
subject to numerous assumptions, risks, and uncertainties, which
change over time. Important factors that may cause actual results
to differ materially from the results discussed in the
forward-looking statements or historical experience include risks
and uncertainties, including the failure by PLx to secure and
maintain relationships with collaborators; risks relating to
clinical trials; risks relating to the commercialization, if any,
of PLx’s proposed product candidates (such as marketing,
regulatory, product liability, supply, competition, and other
risks); dependence on the efforts of third parties; dependence on
intellectual property and risks that PLx may lack the financial
resources and access to capital to fund proposed operations.
Further information on the factors and risks that could affect
PLx’s business, financial conditions and results of operations are
contained in PLx’s filings with the U.S. Securities and
Exchange Commission (SEC), which are available
at www.sec.gov. Other risks and uncertainties are more fully
described in PLx’s prospectus supplement filed with
the SEC on June 12, 2017, and in other filings that
PLx will make going forward. The forward-looking statements
represent PLx’s estimate as of the date hereof only, and PLx
specifically disclaims any duty or obligation to update
forward-looking statements.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Media:Chris Vancheri, Coyne Public RelationsT: 973-588-2043E:
cvancheri@coynepr.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024